InnoDiab Forschung GmbH
- Address
- lock Available on a paid plan
Cardiovascular Research and Kidney Health
At InnoDiab Forschung GmbH in Essen, a major focus is on cardiovascular diseases linked to obesity, type 2 diabetes, and chronic kidney disease. The trials are designed to better understand whether new treatments can lower the risk of heart events, protect kidney function, and reduce inflammation-related complications.
- Studies in atherosclerotic cardiovascular disease and heart failure prevention
- Research on chronic kidney disease and systemic inflammation
- Trials evaluating whether new therapies can reduce major cardiovascular events and improve long-term outcomes
This area reflects a strong effort to improve treatment effectiveness for people with overlapping heart, kidney, and metabolic conditions.
Metabolic Disease and Weight Management
The site conducts extensive research in nutritional and metabolic diseases, especially obesity, overweight, and type 2 diabetes. Many studies are testing new therapies to support weight loss, improve blood sugar control, and address related health risks in adults living with excess body weight.
- Trials in chronic weight management and obesity
- Studies in type 2 diabetes mellitus and type 1 diabetes
- Research focused on improving glycemic control and supporting healthier body weight
These studies help evaluate new options for people with metabolic conditions that often occur together and require long-term management.
Sleep and Respiratory Research
Another key field at this research facility is respiratory tract diseases, with a strong emphasis on obstructive sleep apnea. The clinical trials are exploring whether emerging therapies can improve breathing-related symptoms, reduce sleep disruption, and support better overall health in people with obesity-related sleep disorders.
- Studies in moderate to severe obstructive sleep apnea among adults with overweight or obesity
- Research on sleep apnea outcomes alongside weight reduction
- Trials aimed at improving symptoms and assessing treatment benefit in respiratory and metabolic overlap conditions
This work connects sleep medicine with metabolic care, reflecting the close relationship between breathing disorders, body weight, and cardiometabolic risk.
Integrated Multidisease Clinical Research
The trial portfolio at InnoDiab Forschung GmbH brings together cardiovascular, metabolic, and respiratory research in studies that often include people with more than one condition. The main goal is to test new therapies that may improve weight, blood sugar, sleep-related breathing, and cardiovascular risk at the same time.
- Research in patients with obesity plus type 2 diabetes or cardiovascular disease
- Studies assessing whether new treatments can improve multiple related health outcomes
- Clinical work aimed at better managing common comorbidities linked to excess body weight
With 28 trials and a focused investigator team, the site is contributing to a broad but highly connected research program in cardiometabolic and sleep-related disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 41 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Eli Lilly & Co.2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S10trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in InnoDiab Forschung GmbH
lock Showing 1 of 31 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | Mar 2026 |
IMP list
lock Showing 1 of 41 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 6 | Unknown | 2023-01-30 | 2025-02-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.